Amarin Corp Plc (AMRN)

[hamkypamky]

IF supply is limited and really as difficult to grow as some surmise it's actually a strong plus point for V, especially in hands of BP.

It would give almost extra length to "exclusivity" with the struggle of generics to get sufficient API and hence branded sales would probably have a much slower drop-off compared to other drugs.